Clustering according to urolithin metabotype explains the interindividual variability in the improvement of cardiovascular risk biomarkers in overweight-obese individuals consuming pomegranate: A randomized clinical trial
Clustering according to urolithin metabotype explains the interindividual variability in the improvement of cardiovascular risk biomarkers in overweight-obese individuals consuming pomegranate: A randomized clinical trial
复制标题
DOI：
10.1002/mnfr.201600830
复制
发表时间：
2017-05-01
影响因子：
5.2
通讯作者：
Carlos Espin, Juan
中科院分区：
文献类型：
--
作者：
Gonzalez-Sarrias, Antonio;Garcia-Villalba, Rocio;Carlos Espin, Juan
范围：石榴的降脂特性仍然存在争议，可能是由于多酚（鞣花单宁）代谢存在个体差异。目的：我们旨在研究微生物衍生的鞣花单宁代谢表型，即尿石素代谢型 A、(UM-A)、B (UM-B) 和 0 (UM-0) 是否影响石榴提取物 (PE) 消耗对降脂效果的影响。健康超重肥胖个体中的 18 种心血管风险生物标志物。方法和结果：进行了一项双盲、交叉、剂量反应、随机、安慰剂对照试验。该研究 (POMEcardio) 包括两个测试阶段（剂量 1 和剂量 2，每个阶段持续 3 周）以及每个阶段之间为期 3 周的清除期。 49 名参与者（BMI > 27 kg/m(2)）每天服用一粒（剂量 1，160 毫克酚类/天）或四颗（剂量 2，640 毫克酚类/天）PE 或安慰剂胶囊。值得注意的是，UM-B 个体表现出最高的基线心血管风险。第 2 剂后，总胆固醇 (-15.5 +/- 3.7%)、LDL-胆固醇 (-14.9 +/- 2.1%)、小 LDL-胆固醇 (-47 +/- 7%)、非 HDL-胆固醇 (-11.3 +/- 2.5%)、载脂蛋白-B (-12 +/- 2.2%) 和氧化 LDL-胆固醇 -24 +/- 2.5%）剂量依赖性下降（P < 0.05），但仅在 UM-B 受试者中。这些影响与尿石素的产生和戈登杆菌水平的增加部分相关。三名 (50%) 非生产者 (UM-0) 在食用 PE 后成为生产者。结论：UM 聚类表明含鞣花单宁的食品具有个性化效应，并可以解释有争议的石榴益处。有必要研究尿石素和与每种尿石素相关的微生物群的具体作用。
Scope: The pomegranate lipid-lowering properties remain controversial, probably due to the interindividual variability in polyphenol (ellagitannins) metabolism.Objective: We aimed at investigating whether the microbially derived ellagitannin-metabolizing phenotypes, i.e. urolithin metabotypes A, (UM-A), B (UM-B), and 0 (UM-0), influence the effects of pomegranate extract (PE) consumption on 18 cardiovascular risk biomarkers in healthy overweight-obese individuals.Methods and results: A double-blind, crossover, dose-response, randomized, placebo-controlled trial was conducted. The study (POMEcardio) consisted of two test phases (dose-1 and dose-2, lasting 3 weeks each) and a 3-week washout period between each phase. Forty-nine participants (BMI > 27 kg/m(2)) daily consumed one (dose-1, 160 mg phenolics/day) or four (dose-2, 640 mg phenolics/day) PE or placebo capsules. Notably, UM-B individuals showed the highest baseline cardiovascular risk. After dose-2, total cholesterol (-15.5 +/- 3.7%), LDL-cholesterol (-14.9 +/- 2.1%), small LDL-cholesterol (-47 +/- 7%), non-HDL-cholesterol (-11.3 +/- 2.5%), apolipoprotein-B (-12 +/- 2.2%), and oxidized LDL-cholesterol -24 +/- 2.5%) dose dependently decreased (P < 0.05) but only in UM-B subjects. These effects were partially correlated with urolithin production and the increase in Gordonibacter levels. Three (50%) nonproducers (UM-0) became producers following PE consumption.Conclusions: UM clustering suggests a personalized effect of ellagitannin-containing foods and could explain the controversial pomegranate benefits. Research on the specific role of urolithins and the microbiota associated with each UM is warranted.